Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 14 | 2017 | 253 | 2.350 |
Why?
|
| Cocaine-Related Disorders | 8 | 2017 | 98 | 1.540 |
Why?
|
| Brain | 8 | 2017 | 946 | 1.450 |
Why?
|
| Receptor, Muscarinic M4 | 3 | 2017 | 6 | 1.130 |
Why?
|
| Pyridazines | 3 | 2017 | 7 | 1.130 |
Why?
|
| Thiophenes | 3 | 2017 | 23 | 1.110 |
Why?
|
| Allosteric Regulation | 6 | 2019 | 11 | 1.060 |
Why?
|
| Self Administration | 13 | 2019 | 293 | 0.840 |
Why?
|
| Cognition Disorders | 3 | 2017 | 370 | 0.760 |
Why?
|
| Receptor, Muscarinic M5 | 2 | 2019 | 2 | 0.760 |
Why?
|
| Quinoxalines | 2 | 2012 | 13 | 0.740 |
Why?
|
| Benzazepines | 2 | 2012 | 22 | 0.730 |
Why?
|
| Nicotinic Agonists | 2 | 2012 | 40 | 0.720 |
Why?
|
| Animals | 23 | 2019 | 7569 | 0.680 |
Why?
|
| Antipsychotic Agents | 3 | 2019 | 28 | 0.680 |
Why?
|
| Dopamine Uptake Inhibitors | 6 | 2017 | 117 | 0.640 |
Why?
|
| Positron-Emission Tomography | 6 | 2013 | 167 | 0.630 |
Why?
|
| Oxycodone | 1 | 2019 | 6 | 0.620 |
Why?
|
| Narcotics | 1 | 2019 | 21 | 0.620 |
Why?
|
| Hierarchy, Social | 2 | 2016 | 25 | 0.580 |
Why?
|
| Substance-Related Disorders | 3 | 2019 | 131 | 0.540 |
Why?
|
| Nootropic Agents | 2 | 2016 | 13 | 0.510 |
Why?
|
| Social Behavior | 1 | 2016 | 64 | 0.500 |
Why?
|
| Reversal Learning | 2 | 2012 | 4 | 0.470 |
Why?
|
| Alkynes | 1 | 2015 | 2 | 0.470 |
Why?
|
| Pyridines | 1 | 2015 | 74 | 0.460 |
Why?
|
| Glucose | 2 | 2016 | 184 | 0.460 |
Why?
|
| Sleep | 1 | 2015 | 89 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2017 | 622 | 0.430 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 2011 | 14 | 0.420 |
Why?
|
| Nicotine | 2 | 2012 | 177 | 0.400 |
Why?
|
| Conditioning, Operant | 5 | 2019 | 86 | 0.400 |
Why?
|
| Macaca mulatta | 7 | 2013 | 318 | 0.390 |
Why?
|
| Dopamine | 2 | 2013 | 234 | 0.390 |
Why?
|
| Benzamides | 1 | 2012 | 54 | 0.380 |
Why?
|
| Male | 17 | 2019 | 19641 | 0.360 |
Why?
|
| Discrimination Learning | 1 | 2011 | 19 | 0.350 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 16 | 0.350 |
Why?
|
| Disease Models, Animal | 7 | 2017 | 1012 | 0.340 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2019 | 754 | 0.330 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 126 | 0.320 |
Why?
|
| Memory, Short-Term | 3 | 2015 | 60 | 0.290 |
Why?
|
| Schizophrenia | 2 | 2019 | 32 | 0.280 |
Why?
|
| Rats | 5 | 2019 | 1606 | 0.270 |
Why?
|
| Reward | 3 | 2019 | 65 | 0.260 |
Why?
|
| Behavior, Animal | 3 | 2019 | 253 | 0.250 |
Why?
|
| Cognition | 4 | 2015 | 551 | 0.250 |
Why?
|
| Dizocilpine Maleate | 2 | 2017 | 7 | 0.250 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2016 | 36 | 0.240 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 117 | 0.210 |
Why?
|
| Macaca fascicularis | 5 | 2016 | 431 | 0.200 |
Why?
|
| Primates | 3 | 2013 | 116 | 0.200 |
Why?
|
| Learning | 2 | 2015 | 80 | 0.200 |
Why?
|
| Mice | 3 | 2017 | 2511 | 0.190 |
Why?
|
| Choice Behavior | 2 | 2016 | 86 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2012 | 51 | 0.180 |
Why?
|
| Receptors, Dopamine | 2 | 2012 | 19 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 789 | 0.160 |
Why?
|
| Cholinergic Agents | 2 | 2016 | 8 | 0.160 |
Why?
|
| Receptors, Muscarinic | 1 | 2019 | 9 | 0.150 |
Why?
|
| Cues | 1 | 2019 | 67 | 0.150 |
Why?
|
| Motor Activity | 3 | 2016 | 327 | 0.150 |
Why?
|
| Mice, Knockout | 2 | 2017 | 453 | 0.150 |
Why?
|
| Electroencephalography | 2 | 2015 | 72 | 0.140 |
Why?
|
| Hyperkinesis | 1 | 2017 | 6 | 0.140 |
Why?
|
| Memory Disorders | 1 | 2017 | 54 | 0.130 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 72 | 0.120 |
Why?
|
| Arousal | 1 | 2015 | 19 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 2 | 2014 | 78 | 0.120 |
Why?
|
| Phencyclidine | 1 | 2015 | 1 | 0.120 |
Why?
|
| Polysomnography | 1 | 2015 | 40 | 0.120 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 12 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2016 | 158 | 0.120 |
Why?
|
| Thiazoles | 1 | 2015 | 27 | 0.120 |
Why?
|
| Conditioning, Classical | 1 | 2015 | 26 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 74 | 0.110 |
Why?
|
| Hippocampus | 2 | 2015 | 171 | 0.110 |
Why?
|
| Association Learning | 1 | 2014 | 14 | 0.110 |
Why?
|
| Psychotropic Drugs | 1 | 2014 | 12 | 0.110 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2014 | 26 | 0.110 |
Why?
|
| Dextroamphetamine | 2 | 2013 | 10 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 49 | 0.110 |
Why?
|
| Methylphenidate | 1 | 2013 | 36 | 0.100 |
Why?
|
| Time Factors | 3 | 2015 | 2183 | 0.090 |
Why?
|
| Ligands | 1 | 2012 | 78 | 0.090 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 54 | 0.090 |
Why?
|
| Social Dominance | 1 | 2012 | 18 | 0.090 |
Why?
|
| Putamen | 1 | 2012 | 25 | 0.090 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 25 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2013 | 172 | 0.090 |
Why?
|
| Receptors, Nicotinic | 1 | 2012 | 59 | 0.090 |
Why?
|
| Mecamylamine | 1 | 2011 | 11 | 0.090 |
Why?
|
| Nicotinic Antagonists | 1 | 2011 | 17 | 0.090 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2012 | 97 | 0.090 |
Why?
|
| Haplorhini | 1 | 2011 | 69 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 363 | 0.090 |
Why?
|
| Reinforcement Schedule | 3 | 2017 | 57 | 0.080 |
Why?
|
| Neurons | 1 | 2012 | 416 | 0.070 |
Why?
|
| Social Environment | 1 | 2008 | 77 | 0.070 |
Why?
|
| Humans | 5 | 2019 | 32798 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2019 | 686 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2015 | 459 | 0.050 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2016 | 4 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2016 | 39 | 0.030 |
Why?
|
| Pyramidal Cells | 1 | 2016 | 17 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 64 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 77 | 0.030 |
Why?
|
| Fear | 1 | 2016 | 50 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 258 | 0.030 |
Why?
|
| Action Potentials | 1 | 2016 | 186 | 0.030 |
Why?
|
| Neuropeptide Y | 1 | 2015 | 1 | 0.030 |
Why?
|
| Fourier Analysis | 1 | 2015 | 6 | 0.030 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2015 | 3 | 0.030 |
Why?
|
| Corticosterone | 1 | 2015 | 7 | 0.030 |
Why?
|
| Serotonin | 1 | 2015 | 37 | 0.030 |
Why?
|
| Electromyography | 1 | 2015 | 60 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2015 | 47 | 0.030 |
Why?
|
| Indoles | 1 | 2015 | 56 | 0.030 |
Why?
|
| Cricetulus | 1 | 2014 | 13 | 0.030 |
Why?
|
| Amphetamines | 1 | 2014 | 6 | 0.030 |
Why?
|
| Dogs | 1 | 2014 | 120 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 229 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 282 | 0.030 |
Why?
|
| Cell Line | 1 | 2014 | 433 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2015 | 498 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 79 | 0.020 |
Why?
|
| Food | 1 | 2013 | 42 | 0.020 |
Why?
|
| Homovanillic Acid | 1 | 2012 | 11 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 2012 | 27 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 675 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 271 | 0.020 |
Why?
|
| Food Preferences | 1 | 2008 | 35 | 0.020 |
Why?
|
| Female | 2 | 2015 | 20261 | 0.010 |
Why?
|